PMID- 21838665
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20191112
IS  - 1875-6220 (Electronic)
IS  - 1570-1638 (Linking)
VI  - 10
IP  - 3
DP  - 2013 Sep
TI  - Long-chain omega-3 fatty acid deficiency in mood disorders: rationale for 
      treatment and prevention.
PG  - 233-44
AB  - Major recurrent mood disorders including major depressive disorder (MDD) and 
      bipolar disorder (BD) are associated with significant psychosocial morbidity and 
      excess premature mortality primarily attributable to suicide and coronary heart 
      disease. Limited efficacy and adverse side-effects associated with psychotropic 
      medications used in the treatment of MDD and BD highlight the urgent need to 
      develop safe and efficacious treatments or treatment adjuncts. A body of evidence 
      now indicates that long-chain omega-3 (LCn-3) fatty acid deficiency is a feature 
      associated with MDD and BD. The etiology of LCn-3 deficits in MDD and BD patients 
      may be attributable to both genetic and environmental factors. Dietary LCn-3 
      supplementation is safe and well-tolerated with chronic administration and 
      corrects LCn-3 deficiency in MDD and BD patients. LCn-3 supplementation has been 
      found to augment the therapeutic efficacy of psychotropic medications in the 
      treatment of mood symptoms and to reduce suicidality. Preliminary studies also 
      suggest that LCn-3 supplementation is efficacious as monotherapy in the treatment 
      and prevention of psychopathology in children and adolescents. LCn-3 
      supplementation is also associated with reduced risk for developing coronary 
      heart disease. The overall cost-benefit ratio associated with LCn-3 
      supplementation provides a strong rationale to diagnose and treat LCn-3 
      deficiency in MDD and BD patients, and to prevent LCn-3 deficiency in subjects at 
      high risk for developing these disorders.
FAU - McNamara, Robert K
AU  - McNamara RK
AD  - Department of Psychiatry, University of Cincinnati College of Medicine, 
      Cincinnati, OH 45219-0516, USA. robert.mcnamara@uc.edu
LA  - eng
GR  - AG03617/AG/NIA NIH HHS/United States
GR  - MH083924/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Discov Technol
JT  - Current drug discovery technologies
JID - 101157212
RN  - 0 (Fatty Acids, Omega-3)
SB  - IM
MH  - Animals
MH  - Deficiency Diseases/drug therapy/*metabolism/prevention & control
MH  - Fatty Acids, Omega-3/*metabolism/therapeutic use
MH  - Humans
MH  - Mood Disorders/*metabolism
EDAT- 2011/08/16 06:00
MHDA- 2014/01/01 06:00
CRDT- 2011/08/16 06:00
PHST- 2011/03/02 00:00 [received]
PHST- 2011/04/22 00:00 [revised]
PHST- 2011/06/06 00:00 [accepted]
PHST- 2011/08/16 06:00 [entrez]
PHST- 2011/08/16 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - BSP/CDDT/E-Pub/00079 [pii]
AID - 10.2174/1570163811310030006 [doi]
PST - ppublish
SO  - Curr Drug Discov Technol. 2013 Sep;10(3):233-44. doi: 
      10.2174/1570163811310030006.